Physician profile
Alan B Goldfischer
NPI 1518980093
$2,432.04
in general payments reported to CMS, 2019-2025
27 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $201 · 2021: $316 · 2022: $648 · 2023: $311 · 2024: $215 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.73 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $298.48 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $278.37 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.44 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $253.67 | 2019-2022 | |
| Pfizer INC. | $208.16 | 2019-2024 | |
| Celgene Corporation | $146.38 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $143.47 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ferring Pharmaceuticals INC. | $107.14 | 2019-2025 | Rebyota |
| Braintree Laboratories, INC. | $103.81 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $78.96 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $56.88 | 2019-2023 | Linzess |
| Qol Medical, LLC | $52.24 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $45.99 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.35 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $40.50 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $39.91 | 2025 | Rezdiffra |
| Ardelyx, INC. | $38.61 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $35.87 | 2022-2023 | Dupixent |
| Janssen Scientific Affairs, LLC | $32.83 | 2021 | |
| Gilead Sciences, INC. | $32.09 | 2020-2022 | |
| Exact Sciences Corporation | $30.58 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $21.70 | 2021 | |
| Meridian Bioscience INC. | $20.33 | 2024 | |
| Aimmune Therapeutics, INC. | $18.85 | 2025 | Zenpep |
| Lucid Diagnostics INC. | $14.33 | 2022 | |
| Genzyme Corporation | $12.12 | 2022 | |
| Allergan, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Goldfischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.